Patents by Inventor Michael A. Shultz
Michael A. Shultz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132593Abstract: The present disclosure provides antibodies to V-domain Ig-containing Suppressor of T cell Activation (VISTA) and compositions comprising such antibodies. Also provided are methods of using antibodies that specifically binds to VISTA to treat diseases, e.g., to treat cancer.Type: ApplicationFiled: February 18, 2022Publication date: April 25, 2024Inventors: Shawn P. Iadonato, Thierry Guillaudeux, Eric J. Tarcha, David Scott Johnson, Adam Shultz Adler, Rena Aviva Mizrahi, Yoong Wearn Lim, Michael Asensio
-
Publication number: 20240065636Abstract: An oximeter probe that takes into account tissue color (e.g., skin color or melanin content) to improve accuracy when determining oxygen saturation of tissue. Light is transmitted from a light source into tissue having melanin (e.g., eumelanin or pheomelanin). Light reflected from the tissue is received by a detector. A compensation factor is determined to account for absorption due to the melanin. The oximeter uses this compensation factor and determines a melanin-corrected oxygen saturation value.Type: ApplicationFiled: November 6, 2023Publication date: February 29, 2024Inventors: Kate LeeAnn Bechtel, Kimberly Merritt Shultz, Alex Michael Margiott, George Edward Kechter
-
Publication number: 20220089597Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.Type: ApplicationFiled: March 3, 2021Publication date: March 24, 2022Inventors: Jeffrey T. Bagdanoff, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Mitsunori Kato, Matthew J. LaMarche, Patrick James Sarver, Michael Shultz, Troy Douglas Smith, Sarah Williams
-
Publication number: 20210309663Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.Type: ApplicationFiled: March 3, 2021Publication date: October 7, 2021Inventors: Jeffrey T. Bagdanoff, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Mitsunori Kato, Matthew J. LaMarche, Patrick James Sarver, Michael Shultz, Troy Douglas Smith, Sarah Williams
-
Patent number: 10975080Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.Type: GrantFiled: June 15, 2016Date of Patent: April 13, 2021Assignee: NOVARTIS AGInventors: Jeffrey T. Bagdanoff, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Mitsunori Kato, Matthew J. LaMarche, Patrick James Sarver, Michael Shultz, Troy Douglas Smith, Sarah Williams
-
Publication number: 20190185475Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.Type: ApplicationFiled: June 15, 2016Publication date: June 20, 2019Inventors: Jeffrey T. Bagdanoff, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Mitsunori Kato, Matthew J. LaMarche, Patrick James Sarver, Michael Shultz, Troy Douglas Smith, Sarah Williams
-
Patent number: 9028777Abstract: Provided are cartridges and systems for effecting automated extraction, isolation, and purification of cellular components—such as nucleic acids—from a cellular sample in assay-ready form. Also provided are related methods of effecting such sample processing.Type: GrantFiled: March 23, 2011Date of Patent: May 12, 2015Assignee: Fluidigm CorporationInventors: Kyle W. Hukari, Jason A. A. West, Michael A. Shultz, Richard Milson, Nikolas M. Isely, Michael C. DeRenzi
-
Patent number: 8841291Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).Type: GrantFiled: September 30, 2013Date of Patent: September 23, 2014Assignee: Novartis AGInventors: Leslie Wighton McQuire, Michael Shultz, Ruben Alberto Tommasi, Sven Weiler
-
Patent number: 8683770Abstract: A building assembly utilized in connecting building members together while permitting limited relative movement between the members. The assembly includes a structure such as a track or plate that includes one or more longitudinal slots. Integrally formed in the longitudinal slot is a breakaway washer that receives a fastener that extends into an adjacent structure. When a certain force is applied to the breakaway washer, the breakaway washer breaks away from the slot and this permits the slot to move about the breakaway washer and fastener which results in there being relative movement between two connected structures.Type: GrantFiled: July 6, 2012Date of Patent: April 1, 2014Assignee: The Steel Network, Inc.Inventors: Edward R. diGirolamo, John C. Herrmann, James E. Herrmann, Michael A. Shultz
-
Publication number: 20140031399Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).Type: ApplicationFiled: September 30, 2013Publication date: January 30, 2014Inventors: Leslie Wighton MCQUIRE, Olivier ROGEL, Michael SHULTZ, Ruben Alberto TOMMASI, Sven WEILER
-
Patent number: 8366083Abstract: A tensioning device is provided for tensioning the metal strap of a metal wall structure. The tensioning device includes an elongated bar having a handle and a pair of jaws where one jaw is secured to the elongated bar and another jaw projects from the handle. The jaws are operatively connected between the metal strap and the wall structure. In particular, one jaw is operatively connected or anchored to the wall structure and the other jaw is connected to the metal strap. The handle includes a trigger mechanism for moving the jaws with respect to each other. By actuating the trigger mechanism and closing the jaws, the metal strap is tensioned. After the metal strap is tensioned, it is securely fastened to the wall structure.Type: GrantFiled: October 20, 2009Date of Patent: February 5, 2013Assignee: The Steel Netork, Inc.Inventors: James E. Herrmann, Michael A. Shultz, John C. Herrmann
-
Patent number: 8362063Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.Type: GrantFiled: May 29, 2012Date of Patent: January 29, 2013Assignee: Novartis AGInventors: Ruben Alberto Tommasi, Michael Shultz, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Claus Ehrhardt
-
Publication number: 20120266545Abstract: A building assembly utilized in connecting building members together while permitting limited relative movement between the members. The assembly includes a structure such as a track or plate that includes one or more longitudinal slots. Integrally formed in the longitudinal slot is a breakaway washer that receives a fastener that extends into an adjacent structure. When a certain force is applied to the breakaway washer, the breakaway washer breaks away from the slot and this permits the slot to move about the breakaway washer and fastener which results in there being relative movement between two connected structures.Type: ApplicationFiled: July 6, 2012Publication date: October 25, 2012Applicant: THE STEEL NETWORK, INC.Inventors: Edward R. diGirolamo, John C. Herrmann, James E. Herrmann, Michael A. Shultz
-
Publication number: 20120258954Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.Type: ApplicationFiled: May 29, 2012Publication date: October 11, 2012Applicant: NOVARTIS AGInventors: Claus Ehrhardt, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Michael Shultz, Ruben Alberto Tommasi
-
Patent number: 8222424Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.Type: GrantFiled: March 23, 2009Date of Patent: July 17, 2012Assignee: Novartis AGInventors: Claus Ehrhardt, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Michael Shultz, Ruben Alberto Tommasi
-
Publication number: 20110294205Abstract: Provided are cartridges and systems for effecting automated extraction, isolation, and purification of cellular components—such as nucleic acids—from a cellular sample in assay-ready form. Also provided are related methods of effecting such sample processing.Type: ApplicationFiled: March 23, 2011Publication date: December 1, 2011Inventors: Kyle W. Hukari, Jason A.A. West, Michael A. Shultz, Richard Milson, Nikolas M. Isely, Michael C. DeRenzi
-
Publication number: 20110183964Abstract: The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, Y, Z, and are as defined herein. The present teachings also provide methods of preparing compounds of Formula I and methods of using compounds of Formula I in treating, inhibiting, or preventing pathologic conditions or disorders mediated wholly or in part by deacetylases.Type: ApplicationFiled: April 8, 2011Publication date: July 28, 2011Applicant: NOVARTIS AGInventors: Michael SHULTZ, Christine Hiu-Tung CHEN, Young Shin CHO, Lei JIANG, Jianmei FAN, Gang LIU, Dyuti MAJUMDAR, Jianke LI
-
Publication number: 20110112076Abstract: The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).Type: ApplicationFiled: July 13, 2009Publication date: May 12, 2011Inventors: Leslie Wighton McQuire, Olivier Rogel, Michael Shultz, Ruben Alberto Tommasi, Sven Weiler
-
Publication number: 20110060009Abstract: The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, R4, R5, ring A, and Z are as defined herein. The present teachings also provide methods of preparing compounds of Formula I and methods of use compounds of Formula I in treating pathologic conditions or disorders mediated wholly or in part by deacetylases.Type: ApplicationFiled: August 27, 2010Publication date: March 10, 2011Inventors: Clinton A. BROOKS, Christine Hiu-Tung CHEN, Young Shin CHO, Lei JIANG, Gang LIU, Michael SHULTZ
-
Patent number: RE46844Abstract: A building assembly utilized in connecting building members together while permitting limited relative movement between the members. The assembly includes a structure such as a track or plate that includes one or more longitudinal slots. Integrally formed in the longitudinal slot is a breakaway washer that receives a fastener that extends into an adjacent structure. When a certain force is applied to the breakaway washer, the breakaway washer breaks away from the slot and this permits the slot to move about the breakaway washer and fastener which results in there being relative movement between two connected structures.Type: GrantFiled: April 1, 2016Date of Patent: May 15, 2018Assignee: The Steel Network, Inc.Inventors: Edward R. diGirolamo, John C. Herrmann, James E. Herrmann, Michael A. Shultz